AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02437630 — intervention group
Intervention type: PROCEDURE
Intervention: face mask CPAP
Description: The subjects will wear a facemask with apertures for the oesophageal balloon and fibre-optic devices to cover the mouth and nose. airflow and volume will be recorded with a pneumotachograph and there will be tubing to connect to a positive pressure source (CPAP) to allow mouth pressures to be altered between 0-15cm H20.( 1cm H20 is the pressure produced by a column of water of 1centimetre in depth)
Study NCT02437630 — intervention group
Intervention type: PROCEDURE
Intervention: variation of mouth pressure with CPAP
Description: Once the other procedures are completed the subject will have his mouth pressure varied via application of positive pressure via a commercial CPAP device as used for treatment of obstructive sleep apnoea. The pressure will be varied randomly between 0-15cm H2O (water)for periods of 5 minutes both sitting and lying. Oesophageal balloon recording of intra-thoracic pressure and laryngeal movement and mouth airflow and volume will be recorded simultaneously and at the end of each 5 minute period the subject will be requested to take as big a breath in as possible to allow measurement of functional residual capacity and inspiratory capacity. This will allow us to observe the effect of changing mouth pressure with CPAP on laryngeal aperture and oesophageal pressures and airflow.
Study NCT02437630 — intervention group
Intervention type: OTHER
Intervention: facemask pneumotachograph
Description: The facemask will incorporate a pneumotachograph to allow measurement of airflow and volumes throughout the respiratory cycle. This will allow us to observe the pattern of airflow with varying applied CPAP
Study NCT01557257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-02
Description: Day 1 (40 mg ALO-02 capsule, single dose) Days 2-5 (40 mg ALO-02 capsule, twice daily)
Study NCT01557257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone block
Description: Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
Study NCT01557257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-02
Description: Day 1 (80 mg ALO-02 capsule, single dose) Days 2-5 (80 mg ALO-02 capsule, once daily)
Study NCT01557257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone block
Description: Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose and 11.5 hours after the AM dosing on Days 2-5, (3) 23.5 hours after Day 5 dosing.
Study NCT01557257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OxyContin
Description: Day 1 (40 mg OxyContin tablet, single dose) Days 2-5 (40 mg OxyContin tablet, twice daily)
Study NCT01625832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intermittent coronary sinus occlusion
Description: Patients undergo two 2-minute coronary balloon occlusions. Patients are randomized to CSO first or CSO second.
Study NCT02563392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterine myomectomy with preventive uterine arteries occlusion
Description: laparoscopic uterine myomectomy with preventive uterine arteries occlusion
Study NCT01340898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK 134612
Description: Intramuscular injection
Study NCT01340898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SynflorixTM
Description: Intramuscular injection
Study NCT01340898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/HiberixTM
Description: Intramuscular injection
Study NCT01335984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: The subjects who are assigned in the Telemonitoring group will be provided Blood Pressure monitor, body composition analyzer, and remote monitoring device.~The subjects who are assigned in the Telemonitoring group should visit the site once per every 2 months (8 weeks), and they should measure their blood pressure using a provided blood pressure monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood pressure and body composition, the subjects should make the transmission terminals of remote monitoring device situate near transmission terminal of Smart Care PC and transmit measured information through Smart Care PC into a centralized server of Smart Care Center.
Study NCT01335984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring & Telemedicine
Description: The subjects who are assigned in the Telemonitoring \& Telemedicine group should perform the same remote monitoring procedures as the subjects in the Telemonitoring group.~Since the remote visit substitute for a face to face visit, subjects should reserve the time for remote visit in each clinical trial center. A primary doctor or remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring device and then issue electronic prescriptions.
Study NCT01335984 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: - The subjects who are assigned in the control group will be provided blood Pressure Monitor (Self BP measuring).~The subjects who are assigned in the control group should perform the same blood pressure measurement (2 times a day) same as the test group during the study, and measured results should be recorded in a diary of self blood pressure measurement. In addition, the subjects should visit the site once per every two months (8 weeks).
Study NCT03761524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Customized V plate fixation
Description: (CT) scan is taken for the patients and a customized V pattern plate will be designed .Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position guided by the CAD/CAM plate. MMF will be done.Fracture fragments will be fixed using CAD/CAM plate .
Study NCT03761524 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional miniplates fixation
Description: Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position. MMF will be done.Fracture fragments will be fixed using conventional miniplates fixation of angle fracture.
Study NCT03165734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Oral administration. Supplied in capsules containing 100 mg (as the free base) in red cap/gray body size 0 opaque hard gelatin capsules. The inactive ingredients are microcrystalline cellulose, magnesium stearate, and polyethylene glycol 8000. Each capsule contains 146 mg of pacritinib citrate, which is equivalent to 100 mg pacritinib free base
Study NCT03165734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice medications
Description: Physician's Choice medications will be selected and administered according to the investigator's judgement. Investigators can select individual P/C agents but cannot combine agents or give them sequentially.
Study NCT02563392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic uterine myomectomy without preventive uterine arteries occlusion
Description: laparoscopic uterine myomectomy
Study NCT01707771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y gastric bypass
Description: Active Comparator: Roux-en-Y gastric bypass
Study NCT01707771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet and lifestyle modifications
Description: Active Comparator: diet and lifestyle modifications
Study NCT00501098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin
Description: Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned.
Study NCT01939743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac suppository plus lidocaine gel
Study NCT01939743 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine gel only
Study NCT01939743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine gel only
Study NCT03790488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-4014
Description: Specified dose on specified days
Study NCT02236832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Study NCT02236832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI imaging
Study NCT02236832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI imaging
Study NCT02236832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG recording
Study NCT02236832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EEG recording
Study NCT02236832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological examination
Study NCT02236832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological examination
Study NCT01685840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care
Study NCT01685840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomarker-guided care NT-proBNP
Description: Device: NT-proBNP
Study NCT00224289 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Latanoprost 0.005%
Description: Latanoprost 0.005% ophthalmic solution QHS 8 weeks
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Study NCT04616430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical endoxifen
Description: topical solution
Study NCT04080414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based high-intensity interval training
Description: Participants will be instructed to complete four, high-intensity interval training workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
Study NCT04080414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based moderate-intensity continuous exercise
Description: Participants will be instructed to complete five, moderate-intensity continuous exercise workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
Study NCT02315599 — intervention group
Intervention type: DRUG
Intervention: anti-CD19 CAR
Study NCT04616430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical
Study NCT00824512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGb 761 120 mg
Description: EGb 761® 120 mg bid, orally for 12 to 14 weeks
Study NCT00824512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet BID, orally for 12 to 14 weeks
Study NCT01064713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: Cohort A: 40 mg by mouth every 21 days.~Cohort B. 50 mg by mouth every 21 days.
Study NCT03069547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadriceps Exercise program
Description: The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.~The program details can be requested rom the responsible party. In brief the QE-program consists of:~- A short warm-up and 3 specific exercises for the quadriceps muscle~Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, free weights, etc.
Study NCT03069547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip Exercise program
Description: The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.~The program details be requested rom the responsible party. In brief the HE-program consists of:~- A short warm-up and 3 specific exercises for the hip abductor and extensor muscles~Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, body weight etc.
Study NCT02677467 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood-pressure variability
Description: Day to Night Blood pressure variability
Study NCT02310061 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-vascular lung water measurements by ultrasound (LW-US)
Description: It is widely agreed that the high prevalence of patients with LV dysfunction and heart failure and the lack of simple, non-expensive, bedside techniques that may serve to estimate and monitor parameters of central hemodynamics for guiding the prescription of ultrafiltration (UF) and drug treatment is a factor of major clinical relevance. So,in patients allocated to the active arm, nephrologists register pre- and post-dialysis US-B lines whenever considered useful for volume monitoring.
Study NCT02310061 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard protocol of fluid management in hemodialysis
Description: The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
Study NCT02305160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butantan
Description: Use of Butantan surfactant 100 mg/kg, IT, maximum of 3 doses
Study NCT02305160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
Study NCT02227446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin antibiotic powder
Description: At the time of fracture fixation 1000 mg of Vancomycin powder placed into the wound during wound closure.
Study NCT03259360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POP:
Description: 90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to sexual and gender minority young adults
Study NCT03259360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TSP:
Description: 90 days of Facebook messaging, weekly live sessions targeting tobacco use
Study NCT04571255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-Assisted Relaxation
Description: The music therapy sessions are based on MAR (Music-Assisted Relaxation), a music therapy technique that includes listening to live music, combined with deep diaphragmatic breathing and/or guided imagery relaxation. In a first step, the procedure will explained to the patient and he/she will be asked to close his/her eyes or focus on a fixed point on the ceiling or wall. Subsequently, a verbal introduction will be provided for fostering body and respiratory awareness. Then a mental image will be introduced (e.g., sitting on a beach watching the waves of the sea; being on top of a mountain looking at the horizon; imagining a safe and comfortable personalized place) and live music will be provided based on the principles of entrainment. The patient is asked to let himself/herself guide by the music and breath with the music while concentrating on the imagery. Once the music is over, the patient is again asked to become aware and the experience during the session will verbally discussed.
Study NCT01747746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin
Study NCT01747746 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin and Enoxaparin
Description: Historical Control
Study NCT01970800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: Will obtain daily injections and will evaluate the IGF-1 and IGFBP3 every 3 months
Study NCT04110379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Description: All the dental procedures that will be done will be explained to the child using tell-show-do technique. VR glasses will be introduced to the child using tell-show-do technique and he will be given a choice of cartoon episodes to select from according to his own interest and age appropriate to view during the dental treatment. The child will be given five minutes to get familiar with the VR glasses before starting the dental treatment.
Study NCT04110379 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Behavior Management Techniques
Description: Conventional behavior management techniques will be done to relieve the child's dental anxiety during the dental treatment such as : tell-show-do technique, distraction, and positive reinforcement, according to the child's behavior.
Study NCT04716075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 2x100 MG Oral Capsule + alloSCT
Description: Acalabrutinib 100 mg caps will be administered twice daily for 3-6 months before the intended alloSCT. After restarting acalabrutinib (2x100 mg daily) after the transplant procedure it will be administered for further 9 months. In patients who do not have an acceptable donor acalabrutinib will be administered until disease progression or unacceptable toxicity.
Study NCT04940559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan - Tablet
Description: Oral tablet.
Study NCT01429753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced Imaging Guided LV lead placement
Description: Use of MRI to identify scar and latest activating LV segment as well as CS anatomy. This will be used to guide LV lead placement real-time.
Study NCT01429753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard LV lead placement
Description: Standard LV lead placement not guided by advanced imaging
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benperidol
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benperidol
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluspirilene
Study NCT06102733 — intervention group
Intervention type: BEHAVIORAL
Intervention: Rehabilitation therapy
Description: Chronic pain rehabilitation therapy
Study NCT02268461 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The treatment arm will consist of 3 daily treatment sessions. One treatment session in this study with real rTMS will consist of 600 pulses of 1Hertz rTMS at an intensity of 90% of resting motor threshold (duration 10 minutes) applied to the primary motor area of the contralesional hemisphere.
Study NCT02268461 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive Transcranial Magnetic Stimulation
Description: Sham rTMS utilizes a coil that produces identical noise and tactile sensation to the real coil, but does not emit a magnetic field (0% intensity). Duration and frequency of auditory and tactile stimulation will be identical to the real intervention.
Study NCT01667224 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Actiponin
Description: The dried leaves of G. pentaphyllum leaves were extracted with 50% ethanol and filtered; the filtrate was concentrated under high pressure and high temperature. Damulin An and B, analytical marker of Actiponin, exist more 2.49% and 1.06% respectively in raw material.
Study NCT01667224 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Amount and calorie of placebo are same with Actiponin.
Study NCT01050920 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood collection
Study NCT03242564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vevazz LED
Description: Vevazz LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs.
Study NCT01630928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation
Description: This is a mini-invasive trans-catheter procedure with access via a 6F introducer in one of the femoral arteries. The renal sympathetic nerves arise from T10-L2, arborize around the renal artery and primarily lie within the adventitia. A specialized radiofrequency (RF) ablation catheter is introduced into the renal arteries, first one side, then on the other. Usually, 4-6 two-minute treatments per artery using a proprietary RF generator with automated low power and built-in safety algorithms are sufficient to ablate the sympathetic afferent and efferent fibers.
Study NCT01942161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Low (2 mg/day)
Description: administered 2 mg once daily for 6 weeks
Study NCT01942161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Mid (6 - 12 mg/day)
Description: administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg